Vitaxin
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | alpha-v beta-3 integrin |
| Clinical data | |
| Trade names | Vitaxin |
| ATC code |
|
| Identifiers | |
| ChemSpider |
|
  (what is this?) | |
Vitaxin (MEDI-523) is a humanized monoclonal antibody against the vascular integrin alpha-v beta-3.[1] It is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. Vitaxin was in 2002 being studied for rheumatoid arthritis.[2] It is the developmental precursor of Etaracizumab (MEDI-522). Both are derived from the mouse antibody LM609.[3]
Vitaxin is safe for humans. It has little effect on advanced cancer.[3]
4. [4]== References ==
- ↑ F Vande Woude G, Klein G (2000). Advances in Cancer Research. Academic Press. pp. 27. ISBN 978-0-12-006679-7.
- ↑ Wilder RL (November 2002). "Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases". Annals of the Rheumatic Diseases. 61 Suppl 2: ii96-9. doi:10.1136/ard.61.suppl_2.ii96. PMC 1766704. PMID 12379637.
- 1 2 McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, et al. (November 2005). "Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion". Clinical Cancer Research. 11 (21): 7851–60. doi:10.1158/1078-0432.CCR-05-0262. PMID 16278408.
- ↑ Gramoun, Azza; Shorey, Seema; Bashutski, Jill D.; Dixon, S. Jeffrey; Sims, Stephen M.; Heersche, Johan N. M.; Manolson, Morris F. (2007). "Effects of Vitaxin®, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro". Journal of Cellular Biochemistry. 102 (2): 341–352. doi:10.1002/jcb.21296. PMID 17390341. S2CID 44708059.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.